Literature DB >> 18162266

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

Andreas Wack1, Barbara C Baudner, Anne K Hilbert, Ilaria Manini, Sandra Nuti, Simona Tavarini, Hanno Scheffczik, Mildred Ugozzoli, Manmohan Singh, Jina Kazzaz, Emanuele Montomoli, Giuseppe Del Giudice, Rino Rappuoli, Derek T O'Hagan.   

Abstract

Influenza is controlled by protective titres of neutralizing antibodies, induced with the help of CD4 T-cells, and by antiviral T-cell effector function. Adjuvants are essential for the efficient vaccination of a naïve population against avian influenza. We evaluated a range of adjuvants for their ability to enhance, in naïve mice, protective hemagglutination inhibition (HI) titres, which represent the generally accepted correlate of protection, virus-neutralizing titres and T-cell responses to a new generation influenza vaccine produced in cell culture. The selected adjuvants include alum, calcium phosphate (CAP), MF59, the delivery system poly-(lactide co-glycolide) (PLG) and the immune potentiator CpG. MF59 was clearly the most potent single adjuvant and induced significantly enhanced, long-lasting HI and neutralizing titres and T-cell responses in comparison to all alternatives. The combination of alum, MF59, CAP or PLG with CpG generally induced slightly more potent titres. The addition of CpG to MF59 also induced a more potent Th1 cellular immune response, represented by higher IgG2a titres and the induction of a strongly enhanced IFN-gamma response in splenocytes from immunized mice. These observations have significant implications for the development of new and improved flu vaccines against pandemic and inter-pandemic influenza virus strains.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18162266     DOI: 10.1016/j.vaccine.2007.11.054

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  49 in total

1.  An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice.

Authors:  Yuk-Fai Lau; Lay-Hoon Tang; Amber W McCall; Eng-Eong Ooi; Kanta Subbarao
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59.

Authors:  Ali H Ellebedy; Christopher Lupfer; Hazem E Ghoneim; Jennifer DeBeauchamp; Thirumala-Devi Kanneganti; Richard J Webby
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-26       Impact factor: 11.205

3.  Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.

Authors:  Adrian J Reber; Tatiana Chirkova; Jin Hyang Kim; Weiping Cao; Renata Biber; David K Shay; Suryaprakash Sambhara
Journal:  Aging Dis       Date:  2011-09-30       Impact factor: 6.745

4.  Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predict enhanced immunogenicity in vivo.

Authors:  C Cubillos-Zapata; E Guzman; A Turner; S C Gilbert; H Prentice; J C Hope; B Charleston
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

5.  MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).

Authors:  Barbara C Baudner; Vanessa Ronconi; Daniele Casini; Marco Tortoli; Jina Kazzaz; Manmohan Singh; Lynn D Hawkins; Andreas Wack; Derek T O'Hagan
Journal:  Pharm Res       Date:  2009-03-03       Impact factor: 4.200

Review 6.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

Review 7.  Key roles of adjuvants in modern vaccines.

Authors:  Steven G Reed; Mark T Orr; Christopher B Fox
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

8.  Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon.

Authors:  Xiaoti Guo; Lisa Barroso; Steven M Becker; David M Lyerly; Thomas S Vedvick; Steven G Reed; William A Petri; Eric R Houpt
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

9.  Describing the hexapeptide identity platform between the influenza A H5N1 and Homo sapiens proteomes.

Authors:  Darja Kanduc
Journal:  Biologics       Date:  2010-09-13

10.  A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Authors:  Robert B Mandell; Ramesh Koukuntla; Laura J K Mogler; Andrea K Carzoli; Alexander N Freiberg; Michael R Holbrook; Brian K Martin; William R Staplin; Nicholas N Vahanian; Charles J Link; Ramon Flick
Journal:  Virology       Date:  2009-11-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.